Profund Advisors LLC Acquires 35,700 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Profund Advisors LLC raised its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 297.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,715 shares of the company’s stock after purchasing an additional 35,700 shares during the quarter. Profund Advisors LLC owned 0.11% of Amphastar Pharmaceuticals worth $1,232,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Amphastar Pharmaceuticals by 10.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,762 shares of the company’s stock worth $207,000 after buying an additional 745 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Amphastar Pharmaceuticals by 183.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,422 shares of the company’s stock valued at $37,000 after buying an additional 920 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 1.0% in the 1st quarter. Bessemer Group Inc. now owns 122,046 shares of the company’s stock valued at $2,391,000 after acquiring an additional 1,156 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at about $39,000. Finally, Sterling Capital Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 29.6% in the 3rd quarter. Sterling Capital Management LLC now owns 12,849 shares of the company’s stock valued at $332,000 after acquiring an additional 2,937 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the sale, the executive vice president directly owned 169,203 shares of the company’s stock, valued at approximately $4,050,719.82. This trade represents a 5.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Prins sold 7,973 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the sale, the director directly owned 29,625 shares of the company’s stock, valued at $601,387.50. This represents a 21.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 33,479 shares of company stock worth $763,922. 29.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMPH. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Barclays upped their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 18th. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 16th. Wall Street Zen lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Wells Fargo & Company lifted their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Reduce” and a consensus price target of $22.50.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ:AMPH opened at $27.03 on Tuesday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 10.53, a PEG ratio of 5.14 and a beta of 0.90. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $29.52. The firm’s 50-day moving average is $24.87 and its 200 day moving average is $22.30. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.29. The business had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. Research analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.43 EPS for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.